Alectinib Impurities

veeprho banner
Parent Drug Name Name of Impurity Catalogue No.
Alectinib Alectinib M1b Metabolite VL5710007View
Alectinib Alectinib M4 Metabolite VL5710003View CAS 1256585-04-2
Alectinib Alectinib-D6 DVE00128View CAS 1616374-19-6

Alectinib Related Compound

Alectinib is used to treat non-small-cell lung cancer (NSCLC) that has progressed to other regions of the body.

References

FAQ’s

What type of drug is alectinib?

Alectinib is a tyrosine kinase inhibitor, which is a kind of cancer growth inhibitor. It works by preventing particular chemical messengers from signaling cells to develop. This either prevents or delays the progression of cancer.

Is alectinib used for chemotherapy?

In patients with advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer, alectinib is more effective than conventional chemotherapy (NSCLC)

Is Alecensa show immunotherapy action?

Alecensa is a targeted medication used to treat non-small cell lung cancer (NSCLC) with ALK+ gene alterations. It is not immunotherapy. It is a tyrosine kinase inhibitor that kills cancer cells by targeting a specific region in the cell that causes cancer.

[rfq_list]

Request a quote

1256585-04-2: Alectinib M4 Metabolite

1256585-04-2: Alectinib M4 Metabolite
Catalogue No.

VL5710003

CAS No.

1256585-04-2

Molecular Formula

C₂₈H₃₂N₄O₂

Molecular Weight

456.58 g/mol

Parent drug

Alectinib

IUPAC Name

9-ethyl-8-(4-((2-hydroxyethyl)amino)piperidin-1-yl)-6, 6-dimethyl-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile

Synonyms

N/A

References

Sato-Nakai, Mika, et al. “Metabolites of Alectinib in Human: Their Identification and Pharmacological Activity.” Heliyon, vol. 3, no. 7, July 2017, p. e00354,  https://doi.org/10.1016/j.heliyon.2017.e00354.

Status

In-stock

ListName

Alectinib M4 Metabolite

Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden